Download Opioid Antagonist Therapy

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Drug design wikipedia , lookup

Pharmacokinetics wikipedia , lookup

Toxicodynamics wikipedia , lookup

Compounding wikipedia , lookup

Drug discovery wikipedia , lookup

Electronic prescribing wikipedia , lookup

5-HT2C receptor agonist wikipedia , lookup

Drug interaction wikipedia , lookup

Stimulant wikipedia , lookup

Prescription costs wikipedia , lookup

NK1 receptor antagonist wikipedia , lookup

Psychedelic therapy wikipedia , lookup

Pharmaceutical industry wikipedia , lookup

Dextropropoxyphene wikipedia , lookup

Medication wikipedia , lookup

Biosimilar wikipedia , lookup

Cannabinoid receptor antagonist wikipedia , lookup

List of off-label promotion pharmaceutical settlements wikipedia , lookup

Prescription drug prices in the United States wikipedia , lookup

Pharmacogenomics wikipedia , lookup

Nicotinic agonist wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Neuropharmacology wikipedia , lookup

Polysubstance dependence wikipedia , lookup

Psychopharmacology wikipedia , lookup

Transcript
Garry Thrasher, DO
Medical Director,
ADM Crisis Center Detox Unit
ADM Crisis Center –
Akron, Ohio
Opiate vs. Opioid Opiates are drugs derived from opium such as morphine.
Opioids referred to synthetic or semi‐synthetic opiates and includes heroin, oxycodone, buprenorphine and methadone.
methadone
Opiate Antagonists
 Drugs that compete for the opiate receptors in the 



brain with a higher affinity than opiate agonists
Bl k h i Blocks the opiate receptors
Do not activate the opiate receptors
N l
Naloxone (Narcan)
(N
)
Naltrexone
Naltrexone
 Tablets
 Extended release injectable form ‐ Vivitrol
Naltrexone tablets
 FDA approved to treat Alcohol Dependence and Opioid Dependence after
O
i id D
d
f detoxification
d
ifi i
 Approved for the blockade of opioid receptors  Daily dosing (usually) D il d i (
ll )  Compliance issues ER injectable naltrexone
 FDA approved in 2006 to treat alcohol dependence
 FDA approved in October 2010 to prevent relapse in 



opioid dependence following opioid detoxification
M hl i j i
Monthly injections –
gluteal muscle
l
l l
Superior to the naltrexone tablets
“S
“Supersensitivity” of opioid receptors?
iti it ” f i id t ?
Risk of attempting to “override” the opioid blockade
Naltrexone
 No diversion No drug reward
 Not a controlled drug  Not addictive No withdrawal
 DEA waiver is not required
 Any pharmacy can fill the prescription
yp
y
p
p
 Patient self‐selection
 Psychosocial support is important
y
pp
p
Naltrexone ‐ Indications
 Young adults
 Those highly motivated to abstain from all opioids
 Those who failed agonist therapy
Th h f il d i h
 Those using opioids irregularly  Short history of opioid abuse
 Those wanting to discontinue agonist therapy and are concerned about relapsing
p g
 Those in professions where agonist therapy may be controversial such as pilots or healthcare professionals
 Pre‐/post‐release inmates from correctional facilities P /
l
i
f
i
l f ili i ER injectable naltrexone
 Blocking the reinforcing effects of heroin can lead to gradual extinction of drug seeking and decreased cravings to use opioids
 Relapse prevention!
Contraindications
 Pregnancy Category C
 Post‐Partum/Breast feeding
 Acute Hepatitis
 Severe Liver Disease/Liver Failure
 Patients requiring opioids for pain management?
 Upcoming surgeries.  Allergy
 Chronic Hepatitis C is not a contraindication!
Opiate Antagonist Therapy
 Risk vs. reward
 Patient selection